Profile data is unavailable for this security.
About the company
Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
- Revenue in USD (TTM)122.91m
- Net income in USD-49.20m
- Incorporated2004
- Employees219.00
- LocationCalliditas Therapeutics ABD5, Kungsbron 1,STOCKHOLM 111 22SwedenSWE
- Phone+46 84113005
- Fax+46 86113303
- Websitehttps://www.calliditas.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mind Medicine (MindMed) Inc | 0.00 | -125.32m | 591.51m | 57.00 | -- | 2.99 | -- | -- | -2.94 | -2.94 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -58.14 | -- | -73.35 | -- | -- | -- | -- | -- | -- | -- | 0.0675 | -- | -- | -- | -68.55 | -- | -- | -- |
| Mineralys Therapeutics Inc | 0.00 | -90.80m | 605.71m | 28.00 | -- | 1.85 | -- | -- | -2.18 | -2.18 | 0.00 | 6.61 | 0.00 | -- | -- | 0.00 | -27.78 | -- | -29.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Taysha Gene Therapies Inc | 14.16m | -118.01m | 605.94m | 52.00 | -- | 11.25 | -- | 42.80 | -1.19 | -1.19 | 0.0896 | 0.2879 | 0.1112 | -- | -- | 272,230.80 | -92.70 | -- | -146.13 | -- | -- | -- | -833.60 | -- | -- | -- | 0.4315 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Phathom Pharmaceuticals Inc | 2.59m | -246.63m | 614.62m | 452.00 | -- | -- | -- | 236.94 | -4.41 | -4.41 | 0.047 | -2.54 | 0.0104 | -- | -- | 5,738.94 | -98.55 | -83.26 | -111.44 | -93.77 | 77.14 | -- | -9,507.71 | -135,982.00 | 7.80 | -5.29 | 1.46 | -- | -- | -- | -1.96 | -- | -- | -- |
| Zymeworks Inc | 50.46m | -125.97m | 616.55m | 275.00 | -- | 1.42 | -- | 12.22 | -1.79 | -1.79 | 0.7086 | 6.15 | 0.0874 | -- | 1.03 | 185,529.40 | -21.82 | -22.58 | -24.45 | -26.90 | -- | -- | -249.63 | -91.17 | -- | -- | 0.0002 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| Arbutus Biopharma Corp | 12.99m | -74.39m | 620.88m | 73.00 | -- | 5.17 | -- | 47.81 | -0.4393 | -0.4393 | 0.0766 | 0.6362 | 0.0761 | -- | 5.41 | 177,890.40 | -43.56 | -52.62 | -50.25 | -58.11 | -- | -- | -572.81 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Erasca Inc | 0.00 | -126.86m | 625.90m | 126.00 | -- | 1.38 | -- | -- | -0.8423 | -0.8423 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -30.29 | -- | -32.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
| Harrow Inc | 138.68m | -31.33m | 632.98m | 315.00 | -- | 10.45 | -- | 4.56 | -0.9079 | -0.9079 | 4.09 | 1.71 | 0.5406 | 4.21 | 6.75 | 440,244.40 | -12.21 | -10.86 | -13.79 | -12.71 | 69.77 | 70.75 | -22.59 | -15.35 | 2.75 | -0.3302 | 0.7536 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Calliditas Therapeutics AB - ADR | 122.91m | -49.20m | 635.28m | 219.00 | -- | 53.42 | -- | 5.17 | -1.83 | -1.83 | 4.58 | 0.4197 | 0.7541 | 3.16 | 8.97 | 630,283.30 | -30.19 | -- | -38.05 | -- | 95.01 | -- | -40.03 | -- | 2.62 | -3.99 | 0.8943 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| iTeos Therapeutics Inc | 0.00 | -135.31m | 638.65m | 157.00 | -- | 1.17 | -- | -- | -3.78 | -3.78 | 0.00 | 15.10 | 0.00 | -- | -- | 0.00 | -19.93 | 5.84 | -20.88 | 7.02 | -- | -- | -- | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| Sinovac Biotech Ltd | 448.27m | -105.90m | 639.90m | 3.04k | -- | -- | -- | 1.43 | -1.08 | -1.08 | 4.19 | 87.41 | 0.0323 | 1.13 | 0.9175 | 147,602.60 | -1.86 | 36.14 | -2.80 | 58.37 | 59.51 | 90.77 | -57.63 | 65.87 | 10.18 | -- | 0.0207 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| Hillevax Inc | 0.00 | -143.51m | 640.90m | 90.00 | -- | 2.65 | -- | -- | -3.29 | -3.29 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -46.66 | -- | -50.34 | -- | -- | -- | -- | -- | -- | -- | 0.0963 | -- | -- | -- | 22.68 | -- | -- | -- |
| Arrivent Biopharma Inc | -100.00bn | -100.00bn | 644.42m | 40.00 | -- | 2.03 | -- | -- | -- | -- | -- | 9.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| AnaptysBio Inc | 22.96m | -163.30m | 653.19m | 117.00 | -- | 13.67 | -- | 28.45 | -6.13 | -6.13 | 0.862 | 1.75 | 0.048 | -- | 5.33 | 196,256.40 | -34.11 | -18.08 | -36.72 | -18.96 | -- | -- | -711.18 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| Dianthus Therapeutics Inc | 3.22m | -50.21m | 661.83m | 53.00 | -- | 1.78 | -- | 205.28 | -3.20 | -3.20 | 0.2721 | 12.70 | 0.0138 | -- | -- | 60,830.19 | -21.56 | -41.40 | -22.27 | -44.70 | -- | -- | -1,557.51 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| Castle Biosciences Inc | 250.73m | -30.80m | 672.79m | 610.00 | -- | 1.67 | -- | 2.68 | -1.15 | -1.15 | 9.28 | 14.59 | 0.5664 | 8.01 | 7.12 | 411,024.60 | -6.96 | -9.43 | -7.48 | -10.17 | 80.58 | 80.58 | -12.28 | -28.46 | 9.02 | -- | 0.0243 | -- | 60.38 | 57.35 | 14.41 | -- | 117.94 | -- |
Data as of May 24 2024. Currency figures normalised to Calliditas Therapeutics AB's reporting currency: US Dollar USD
2.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Mar 2024 | 750.00k | 2.52% |
| DWS Investment GmbHas of 31 Mar 2024 | 50.55k | 0.17% |
| Ironwood Investment Management LLCas of 31 Mar 2024 | 25.51k | 0.09% |
| Citadel Securities LLCas of 31 Mar 2024 | 14.59k | 0.05% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 10.28k | 0.03% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 5.88k | 0.02% |
| Desjardins Securities, Inc.as of 31 Mar 2024 | 3.99k | 0.01% |
| Wells Fargo Clearing Services LLCas of 31 Mar 2024 | 3.76k | 0.01% |
| Optiver US LLCas of 31 Mar 2024 | 2.53k | 0.01% |
| Arbor Point Advisors LLCas of 31 Mar 2024 | 1.10k | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
